Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 688

1.

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Genes Chromosomes Cancer. 2008 Oct;47(10):853-9. doi: 10.1002/gcc.20589.

2.

Molecular characterization of an Italian series of sporadic GISTs.

Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, Garuti A, Ghiorzo P, Martinuzzi C, Toffolatti L; Liguria GIST Unit, Bianchi Scarrà G.

Gastric Cancer. 2013 Oct;16(4):596-601. doi: 10.1007/s10120-012-0213-y. Epub 2013 Jan 5.

PMID:
23291969
3.

V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.

Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP.

J Clin Pathol. 2009 Jul;62(7):613-6. doi: 10.1136/jcp.2009.064550.

PMID:
19561230
4.

KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.

Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M.

Clin Cancer Res. 2012 Mar 15;18(6):1769-76. doi: 10.1158/1078-0432.CCR-11-2230. Epub 2012 Jan 26.

5.
6.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

7.

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.

Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P.

Gastroenterology. 2005 Feb;128(2):270-9.

PMID:
15685537
8.

KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.

Zheng S, Huang KE, Pan YL, Zhou Y, Pan SD, Li X, Jia J, Zheng XL, Tao DY.

Gastric Cancer. 2015 Oct;18(4):796-802. doi: 10.1007/s10120-014-0414-7. Epub 2014 Aug 15.

PMID:
25182956
9.

High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.

Künstlinger H, Binot E, Merkelbach-Bruse S, Huss S, Wardelmann E, Buettner R, Schildhaus HU.

Hum Pathol. 2014 Mar;45(3):573-82. doi: 10.1016/j.humpath.2013.10.025. Epub 2013 Nov 4.

PMID:
24444465
10.

[The importance of mutational status in prognosis and therapy of GIST].

Comandone A, Boglione A.

Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950. Italian.

PMID:
25621775
11.

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.

Med Oncol. 2008;25(2):207-13. doi: 10.1007/s12032-007-9014-2. Epub 2007 Oct 6.

PMID:
18488160
12.

The role of KIT in the management of patients with gastrointestinal stromal tumors.

Hornick JL, Fletcher CD.

Hum Pathol. 2007 May;38(5):679-87. Review.

PMID:
17437861
13.

KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.

Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, Casali PG, Maestro R, Dei Tos AP.

Am J Surg Pathol. 2015 Jul;39(7):922-30. doi: 10.1097/PAS.0000000000000418.

PMID:
25970686
14.

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.

Søreide K, Sandvik OM, Søreide JA, Gudlaugsson E, Mangseth K, Haugland HK.

Clin Transl Oncol. 2012 Aug;14(8):619-29. doi: 10.1007/s12094-012-0851-x. Epub 2012 Jul 18.

PMID:
22855146
15.

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP.

Clin Cancer Res. 2005 Jun 1;11(11):4182-90.

16.

[Translational research and diagnosis in GIST].

Wardelmann E.

Pathologe. 2012 Nov;33 Suppl 2:273-7. doi: 10.1007/s00292-012-1682-9. Review. German.

PMID:
22968735
17.

Imatinib treatment for gastrointestinal stromal tumour (GIST).

Lopes LF, Bacchi CE.

J Cell Mol Med. 2010 Jan;14(1-2):42-50. doi: 10.1111/j.1582-4934.2009.00983.x. Epub 2009 Nov 28. Review.

18.

Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.

Jasek K, Buzalkova V, Minarik G, Stanclova A, Szepe P, Plank L, Lasabova Z.

Virchows Arch. 2017 Jan;470(1):29-36. doi: 10.1007/s00428-016-2044-4. Epub 2016 Nov 18.

PMID:
27864688
19.

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.

Wang CM, Huang K, Zhou Y, Du CY, Ye YW, Fu H, Zhou XY, Shi YQ.

J Cancer Res Clin Oncol. 2010 Jul;136(7):1065-71. doi: 10.1007/s00432-009-0753-7. Epub 2009 Dec 31.

PMID:
20043176
20.

Molecular research directions in the management of gastrointestinal stromal tumors.

Tarn C, Godwin AK.

Curr Treat Options Oncol. 2005 Nov;6(6):473-86. Review.

PMID:
16242052

Supplemental Content

Support Center